Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 100

Sort by

Sort Order Select

Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Blood (2022) 140 (17): 1845–1857.

https://doi.org/10.1182/blood.2021014586

Published: 2022

Includes: Supplemental data

Journal Articles

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman

Blood (2021) 138 (Supplement 1): 691.

https://doi.org/10.1182/blood-2021-150743

Published: 2021

Journal Articles

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Blood (2021) 138 (Supplement 1): 700.

https://doi.org/10.1182/blood-2021-145379

Published: 2021

Journal Articles

Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

Blood (2021) 138 (Supplement 1): 695.

https://doi.org/10.1182/blood-2021-145436

Published: 2021

Journal Articles

Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3 -Mutated AML: Results of a Phase 1 Study

Jessica K. Altman, Bhavana Bhatnagar, Sameem Abedin, Amanda Przespolewski, Prapti A. Patel, Gary J. Schiller, Stanley Gill, Dhruva Patel, Linyi Fan, Ramon V. Tiu, Stephen A. Strickland

Blood (2021) 138 (Supplement 1): 2343.

https://doi.org/10.1182/blood-2021-150707

Published: 2021

Journal Articles

A Phase 1, Dose-Escalation Study of Gilteritinib Combined with Chemotherapy in Patients Aged 6 Months to <21 Years with FLT3 Internal Tandem Duplication-Positive Relapsed or Refractory AML

Philip Connor, Linyi Fan, Stanley Gill, Jason E. Hill, Nisha Philipose, David Delgado, Ramon V. Tiu, Dirk Reinhardt

Blood (2021) 138 (Supplement 1): 2315.

https://doi.org/10.1182/blood-2021-147862

Published: 2021

Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137685

Published: 2020

Journal Articles

Clinical Outcomes Following Treatment with Gilteritinib or Quizartinib in Patients with Relapsed/Refractory FLT3 -ITD+ Acute Myeloid Leukemia

Alexander E. Perl, MD, Qiaoyang Lu, MS, Alan Fan, MS Pharm, Nahla Hasabou, MD, Erhan Berrak, MD, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136118

Published: 2020

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Naval Daver, MD, Jessica K. Altman, MD, Joseph Maly, MD, Mark Levis, MD PhD, Ellen Ritchie, MD, Mark Litzow, MD, James K. McCloskey, MD, Catherine C. Smith, MD, Gary J. Schiller, MD, Terrence Bradley, MD, Ramon V. Tiu, MD, Wan-Jen Hong, MD, Bo Tong, PhD, Qin Qin, MS, Kimberley Dilley, MD MPH, Alexander E. Perl, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-139705

Published: 2020

Journal Articles

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Alexander E. Perl, MD, Jessica K. Altman, MD, Naoko Hosono, MD PhD, Pau Montesinos, MD PhD, Nikolai A. Podoltsev, MD PhD, Giovanni Martinelli, MD, Catherine C. Smith, MD, Mark Levis, MD PhD, Christoph Röllig, Prof., MD, Marco Groß-Langenhoff, PhD, Nahla Hasabou, MD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-136395

Published: 2020

Journal Articles

Clinical Evaluation of Xpert® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1

Michael J. Mauro, MD, Richard D. Press, MD PhD, David S. Snyder, MD, Qin Huang, MD PhD, Javier Pinilla-Ibarz, Dahui Qin, MD PhD, Christina Lockwood, PhD, Jacqueline E. Payton, MD PhD, Geoffrey L. Uy, MD, Matt E. Kalaycio, MD, Ramon V. Tiu, MD BS, Vivian Oehler, MD, Gwo-Jen Day, PhD, Wendy Wong, Michael P. Bates, MD, Jerald P. Radich

Blood (2015) 126 (23): 5170.

https://doi.org/10.1182/blood.V126.23.5170.5170

Published: 2015

Journal Articles

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Saroj Vadhan-Raj, MD, Rafat Abonour, Jonathan W. Goldman, MD, David A. Smith, MD, Christopher A. Slapak, MD, Ramon V. Tiu, MD, Xuejing Wang, Sophie Callies, Joanne Cox, Jay L. Tuttle, PhD, Yiu-Keung (James) Lau, MD PhD, Eric J. Roeland, MD

Blood (2015) 126 (23): 537.

https://doi.org/10.1182/blood.V126.23.537.537

Published: 2015

Journal Articles

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Blood (2015) 125 (12): 1857–1865.

https://doi.org/10.1182/blood-2014-10-607341

Published: 2015

Journal Articles

Somatic Mutations in the Wiskott-Aldrich Syndrome Protein Family Member 3 ( WASF3 ) Are Associated with Poor Prognosis in Myeloid Malignancies

Valeria Visconte, PhD, Ali Tabarroki, MD, Li Zhang, Aaron T. Gerds, MD MS, Heesun J. Rogers, MD PhD, Velizar Shivarov, MD, PhD, John Barnard, Ramon V. Tiu, MD

Blood (2014) 124 (21): 4600.

https://doi.org/10.1182/blood.V124.21.4600.4600

Published: 2014

Journal Articles

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Ali Tabarroki, MD, Daniel Lindner, MD PhD, Valeria Visconte, PhD, Nikolaos Papandantonakis, Jing Ai, MD PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Tracy Cinalli, RN, Kristin Colaluca, RN, Gina Rupp, John Desamito, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 4587.

https://doi.org/10.1182/blood.V124.21.4587.4587

Published: 2014

Journal Articles

Impact of Non- JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib

Jing Ai, MD PhD, Valeria Visconte, PhD, Ali Tabarroki, MD, Ahmad Zarzour, MD, Christopher Gerace, Karam Al-Issa, MD, Evan Hsi, Yasmine Hirbawi, Betty K. Hamilton, MD, Eric D. Hsi, MD, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 3194.

https://doi.org/10.1182/blood.V124.21.3194.3194

Published: 2014

Journal Articles

Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib

Ahmad Zarzour, MD, Ali Tabarroki, MD, Valeria Visconte, PhD, Rokana Taftaf, MD, Heesun J. Rogers, MD PhD, Jing Ai, MD PhD, Nikolaos Papadantonakis, MD PhD, Alan E. Lichtin, Yogen Saunthararajah, MD, Brady L Stein, MDMHS, Ramon V. Tiu, MD

Blood (2014) 124 (21): 1834.

https://doi.org/10.1182/blood.V124.21.1834.1834

Published: 2014

Journal Articles

Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib

Ahmad Zarzour, MD, Ali Tabarroki, MD, Rokana Taftaf, MD, Valeria Visconte, PhD, Jing Ai, MD PhD, Betty K. Hamilton, MD, Nikolaos Papadantonakis, MD PhD, Alan E. Lichtin, Leonard J. Horwitz, MD, Anjali S. Advani, MD, Mikkael A. Sekeres, MD MS, Ramon V. Tiu, MD

Blood (2014) 124 (21): 1835.

https://doi.org/10.1182/blood.V124.21.1835.1835

Published: 2014

Journal Articles

Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia

Valeria Visconte, PhD, Ali Tabarroki, MD, Christopher Gerace, Karam Al-Issa, MD, Eric D. Hsi, MD, Heesun J. Rogers, MD PhD, Mikkael A. Sekeres, MD MS, Bernard J. Silver, MD, Alan E. Lichtin, MD, Sudipto Mukherjee, MD MPH, Ramon V. Tiu, MD

Blood (2014) 124 (21): 5597.

https://doi.org/10.1182/blood.V124.21.5597.5597

Published: 2014

Journal Articles

Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1 ), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)

Valeria Visconte, PhD, Ali Tabarroki, MD, John Barnard, Li Zhang, Juraj Bodo, PhD, Reda Mahfouz, MD, Betty K. Hamilton, MD, Mikkael Sekeres, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Yogen Saunthararajah, MD, Velizar Shivarov, MD, PhD, Shashirekha Shetty, PhD, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 3250.

https://doi.org/10.1182/blood.V124.21.3250.3250

Published: 2014

NARROW

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3 -Mutated AML: Results of a Phase 1 Study

A Phase 1, Dose-Escalation Study of Gilteritinib Combined with Chemotherapy in Patients Aged 6 Months to <21 Years with FLT3 Internal Tandem Duplication-Positive Relapsed or Refractory AML

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Clinical Outcomes Following Treatment with Gilteritinib or Quizartinib in Patients with Relapsed/Refractory FLT3 -ITD+ Acute Myeloid Leukemia

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Clinical Evaluation of Xpert® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Somatic Mutations in the Wiskott-Aldrich Syndrome Protein Family Member 3 ( WASF3 ) Are Associated with Poor Prognosis in Myeloid Malignancies

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Impact of Non- JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib

Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib

Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib

Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia

Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1 ), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only